Glycaemic control and weight loss with semaglutide in type 2 diabetes

Affiliations

¹ Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, 2650 Hvidovre, Denmark; NNF Center for Basic Metabolic Research and Department of Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: sten.madsbad@regionh.dk.
² NNF Center for Basic Metabolic Research and Department of Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Comment

Sten Madsbad et al. Lancet Diabetes Endocrinol. 2017 May.

. 2017 May;5(5):315-317.

doi: 10.1016/S2213-8587(17)30094-3. Epub 2017 Apr 3.

¹ Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, 2650 Hvidovre, Denmark; NNF Center for Basic Metabolic Research and Department of Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: sten.madsbad@regionh.dk.
² NNF Center for Basic Metabolic Research and Department of Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

No abstract available

Comment on

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH. Aroda VR, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):355-366. doi: 10.1016/S2213-8587(17)30085-2. Epub 2017 Mar 23. Lancet Diabetes Endocrinol. 2017. PMID: 28344112 Clinical Trial.
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Ahrén B, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X. Epub 2017 Apr 3. Lancet Diabetes Endocrinol. 2017. PMID: 28385659 Clinical Trial.